Updated immunisation reference page: Pneumococcal
MVEC recently updated in pneumococcal reference page to reflect upcoming changes to the National Immunisation Program. From 1 July 2026, the vaccine Capvaxive will replace Prevenar 13 and Pneumovax 23 for adults.
The newly updated page includes information on Capvaxive administration and groups eligible to be vaccinated under the NIP.
New immunisation reference page: Inborn errors of immunity
MVEC recently published a new immunisation reference page on inborn errors of immunity (IEI, previously referred to as primary immunodeficiencies). IEIs comprise a broad group of inherited disorders affecting one or more components of the immune system.
The new reference page outlines immunisation recommendations, contraindications and responses to commonly asked questions.
MVEC: Inborn errors of immunity
New immunisation reference page: Discoloured leg syndrome
MVEC has published a new immunisation reference page on the rare phenomenon of discoloured leg syndrome (DLS). DLS is a transient condition that can occur after an individual receives an injected vaccine.
The new reference page includes information on DLS diagnosis, association and incidence, treatment, and implications for future vaccine doses.
MVEC: Discoloured leg syndrome
Updated immunisation reference page: Respiratory syncytial virus (RSV)
MVEC has recently updated its RSV immunisation reference page to reflect the upcoming addition of RSV vaccination for older adults to the National Immunisation Program (NIP).
The updated page includes details on RSV vaccines (for adults only, there are no vaccines registered for infants/children) and monoclonal antibodies, as well as information on disease transmission and epidemiology.
MVEC: Respiratory syncytial virus (RSV)
Updated immunisation reference page: Older population's immunisation recommendations
MVEC has updated its older population's immunisation recommendations reference page to reflect the addition of respiratory syncytial virus (RSV) vaccination to the National Immunisation Program (NIP) for older adults.
The page provides background information on the immunisation needs of older adults, and outlines vaccine recommendations for older adults (both funded and un-funded vaccines).
Visit the newly updated page at MVEC: Older population's immunisation recommendations.
Updated immunisation reference page: Translated 2026 influenza page
Translated version of MVEC’s recently updated 2026 influenza reference page are now available. This reference is available to read in Vietnamese, Hindi and Simplified Chinese.
MVEC’s influenza reference page details recommendations for flu vaccination in 2026, including:
- influenza strains included in this year’s vaccines
- brands available by age and funding
- commonly asked questions.
Switch between languages using the dropdown box at the beginning of the page.
MVEC: Influenza
New immunisation reference page: Dengue
Dengue, or dengue fever, is a viral illness caused by infection with the dengue virus (DENV). Primarily transmitted via mosquitos, dengue is endemic in more than 100 countries across tropical and sub-tropical areas in the Pacific, Asia, Africa and the America.
MVEC has recently published a new immunisation reference page on dengue, which includes information on symptoms and transmission, epidemiology, and prevention.
Updated immunisation reference page: Specialist immunisation services
MVEC’s Specialist immunisation services page was recently updated to include details of the new antenatal vaccination service at Northern Health.
Find more details about the new service at MVEC: Specialist immunisation services.
Updated immunisation reference page: Japanese encephalitis
Spread to humans through mosquito bites, Japanese encephalitis (JE) is a rare but potentially serious disease.
Booster doses are now recommended for individuals who remain at ongoing risk of exposure, to be administered 1 to 2 years following the primary course of vaccination. (Boosters are recommended where primary course was with JEspect, or where primary course was administered with Imojev at < 18 years).
MVEC’s JE reference page has been updated with the booster recommendations. The page includes information on JE disease, epidemiology and prevention recommendations.
Updated immunisation reference page: Needle anxiety and phobia
MVEC has recently updated our reference page on needle anxiety and phobia. The updated reference page provides recommendations for managing needle anxiety and needle phobia across age groups.
This reference page is intended to be helpful for for individuals experiencing needle anxiety or needle phobia, caregivers/parents/support people for individuals who need support, and vaccine providers.
MVEC: Needle anxiety and phobia